Epic Sciences has appointed Lloyd Sanders as president and CEO. He will be replacing Murali Prahalad, who is stepping down and has been appointed to the board of directors. Sanders joins the firm with 20 years of diagnostic and pharmaceutical industry experience. He previously served as president of Myriad Genetics' oncology segment. Prior to Myriad, Sanders served as chief operating officer at Dey Pharma. Before Dey Pharma, Sanders worked at Genta, where he acted as VP of marketing and later COO.
Rob Treanor, Andrew Campbell
Sphere Fluidics has appointed Rob Treanor and Andrew Campbell as director of operations and director of finance, respectively. Treanor has previously held positions running large logistics and supply teams within the biotechnology sector. Campbell previously held senior positions at various global life sciences companies, including Charles Rivers and PerkinElmer Life Sciences.
Quanterix said this week that it has appointed Amol Chaubal as CFO, effective April 12, 2019. He replaces Joseph Driscoll, who is stepping down as CFO. Chaubal joins Quanterix from medical device firm Smith & Nephew, where he currently serves as CFO of global operations. Prior to Smith & Nephew, he served as corporate VP and head of finance for Parexel's CRS business, and has also held various roles at Novartis, including CFO North America – Vaccines & Diagnostics.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.